Loading…
← CockpitCompetitor Analysis › YPSN.SW Ypsomed Holding AGOpen in the cockpit ↗

Ypsomed Holding AGYPSN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties

Swiss maker of injection pens, insulin pumps and auto-injector devices delivering diabetes and other injectable drugs.

≈ A device-only peer to Insulet, supplying pens/pumps rather than the drugMomentum leader 87
Mkt cap
$6.83B
US dollars, full cap
Free float
20%
of shares outstanding
$/day
$8.48M
20-day average traded
Fwd P/E
31.7×
forward earnings
ROIC−WACC
+9.6 pp
WACC 5.7%
Hurdle
n/a
no reverse DCF
Next earnings
189 days
26 May 2027
Close · CHFCHF 438.40
1D+3.9%
1W+5.9%
1M+16.0%
3M+8.2%
6M+26.9%
YTD+33.7%
1Y+32.5%
ATR %2.5%
52w lowhighat the 52-week high

What Ypsomed does

Swiss maker of injection pens, insulin pumps and auto-injector devices delivering diabetes and other injectable drugs.

Mostly designs and makes injection devices that drug companies build into their own products, paid through long-term supply agreements, so volumes continue for as long as the partner's drug sells. Its own diabetes pumps and pens are sold through pharmacies and insurers. Founder Willy Michel remains the controlling shareholder.

In one line: A device-only peer to Insulet, supplying pens/pumps rather than the drug.

Products and services

  • Insulin pumps (mylife)
  • Pen injectors/needles
  • Auto-injectors for pharma partners
  • CGM integration

Customers

  • Diabetes patients
  • Pharma companies needing injector devices (e.g. GL

Where it sits in the supply chain

  • Health care
  • Drug-delivery devices
  • Injection pens & insulin pumps

What could go right

  • GLP-1/obesity drug delivery-device demand
  • Pump share gains from multiple-daily-injection patients

What could go wrong

  • Reimbursement pressure on device pricing
  • Customer concentration in pharma partnerships

Moat: narrow (switching costs, IP, customer qualification). Long device-qualification cycles with pharma partners and patient habituation create stickiness.

Headquarters: Burgdorf, Switzerland · Founded: 1984 · Employees: 2,025

Named competitors

Ypsomed at a glance

Size Ypsomed (YPSN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $6.83B, the 46th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 438.40 on 18 Nov 2026.

Performance Over six months the shares gained 26.9%, against +26.4% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue fell 12.9% over the last twelve months (peer median +8.1%); the operating margin is 30.4% (peer median 15.7%).

Valuation It trades at 31.7× forward earnings against a peer median of 20.8× (3rd most expensive of 21).

Capital Return on invested capital runs 9.6 points above its cost of capital (5.7% WACC).

Next results Next results expected around 26 May 2027 (exchange calendar; dates can move).

Relative performance

10011012013021 May 202621 Aug 202618 Nov 2026YPSN.SW 128Peer median 128
Six months, rebased to 100: Ypsomed against the median of its 20 peers (local-currency closes).

Ypsomed financials

Reported figures in CHF; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 686MCHF 731MCHF 749MCHF 548MCHF 497M
Revenue growth—-2%+37%+10%—
Gross profitCHF 322MCHF 315MCHF 292MCHF 220MCHF 141M
EBITDACHF 301MCHF 267MCHF 213MCHF 156MCHF 116M
Net incomeCHF 168MCHF 222MCHF 87.5MCHF 78.4MCHF 51.3M
Free cash flow-CHF 5.93MCHF 11.2M-CHF 57.4MCHF 46.8MCHF 30.7M
Capital expenditureCHF 320MCHF 323MCHF 277MCHF 195MCHF 169M
Total debtn/aCHF 261MCHF 367MCHF 256MCHF 157M

Quarterly statements and history in the cockpit →

Ypsomed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%0%+10%+20%CTECCOHLNTHTFX7747BLCOGETI-B30083268861768697701HAELIVNMMSIGMEDBRKR300677DIAPODDMMEDYPSN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Ypsomed is the large dot.

Fundamentals: revenue growth against valuation

-10%0%+10%+20%+30%15×20×25×30×CTECCOHLNTHTFX7747BLCOGETI-B30083268861768697701HAELIVNGMEDBRKR300677DIAPODDMMEDYPSN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ypsomed is the large dot.

Ypsomed competitors and peer comparison

Head to head with its named competitors (YPSN.SW vs PODD vs TNDM vs NOVO-B.CO)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ypsomed YPSN.SW$6.83B+27%-13%30%31.7×n/a
Insulet PODD$9.71B-11%+26%18%18.6×10.6%
Tandem Diabetes Care TNDM$1.19B+13%+7%-2%n/an/a
Novo Nordisk A/S NOVO-B.CO$177B-6%+6%48%11.8×-0.5%
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Ypsomed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ypsomed against its 20 peers (data as of 18 Nov 2026)
MeasureYPSN.SWPeer medianRank in peer set
1-month return+16.0%+11.2%5th highest of 21
6-month return+26.9%+26.4%11th highest of 21
Distance from 52-week high0.0%-7.2%highest of 21
Revenue growth (TTM)-12.9%+8.1%2nd lowest of 21
Operating margin30.4%15.7%4th highest of 21
Forward P/E31.7×20.8×3rd most expensive of 21
ROIC minus cost of capital+9.6 pp+3.2 pp6th highest of 21
EV / EBITDA20.1×14.0×2nd most expensive of 18
Net debt / EBITDA1.0×0.5×8th most indebted of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ypsomed YPSN.SWSwitzerland$6.83B+27%-13%30%31.7×n/an/a
ConvaTec CTEC.LUnited Kingdom$6.78B+37%+2%16%17.7×17.2%+4.6%
Cochlear COH.AXAustralia$6.72B+58%-1%13%29.1×23.9%+9.3%
Lantheus LNTHUnited States$6.67B+6%+2%19%15.5×0.4%+35.3%
Teleflex TFXUnited States$6.58B+23%-29%12%16.7×16.5%-4.7%
Asahi Intecc 7747.TJapan$7.09B+24%+23%32%29.7×15.1%+18.8%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
APT Medical 688617.SSChina$6.06B+23%+28%37%38.6×9.0%+40.1%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Haemonetics HAEUnited States$5.59B+106%+4%19%20.7×10.9%+8.9%
LivaNova LIVNUnited States$5.21B+28%+12%15%20.9×14.2%+8.2%
Merit Medical Systems MMSIUnited States$5.15B+33%+9%14%19.1×12.6%+9.5%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Intco Medical Technology 300677.SZChina$4.82B-2%+33%20%18.5×-3.5%-6.4%
DiaSorin DIA.MIItaly$4.81B+24%-3%24%20.5×4.1%+6.3%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
MiniMed MMEDUnited States$4.78B+46%+14%14%26.3×n/an/a

Questions

Who are Ypsomed's main competitors?
Named competitors: Insulet (PODD), Tandem Diabetes Care (TNDM), Novo Nordisk (device unit) (NOVO-B.CO), SHL Medical (private or unlisted), Medtronic Diabetes (MDT). The cockpit's measured peer set (industry) also includes ConvaTec (CTEC.L), Cochlear (COH.AX), Lantheus (LNTH), Teleflex (TFX), Asahi Intecc (7747.T), Bausch + Lomb (BLCO.TO).
Is Ypsomed expensive compared with its peers?
On forward p/e it trades at 31.7× against a peer median of 20.8×, 3rd most expensive of 21 in its peer set.
How has Ypsomed stock performed?
Over six months to 18 Nov 2026 the shares returned +26.9% against +26.4% for the median peer; over one year +32.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.